Abstract CT249: An open-label, multicenter, phase 2 study of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) Part 2
Year: 2025
Type: conference-abstract
Source: Cancer Research
Authors: Funda Meric-Bernstam, Jung-Yun Lee, Vicky Makker, Ana Oaknin, Chiedozie Anoka, Lindsey Jung, Soham Puvvada, João Simões, Do Youn Oh
Institutions: The University of Texas MD Anderson Cancer Center, Yonsei University, Severance Hospital, Yonsei University Health System, Yonsei Cancer Hospital, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, AstraZeneca (United States), AstraZeneca (United Kingdom), Seoul National University Hospital
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4409821692